302 related articles for article (PubMed ID: 23598889)
1. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Grisham RN; Adaniel C; Hyman DM; Ma W; Iasonos A; Aghajanian C; Konner J
Int J Gynecol Cancer; 2012 Jun; 22(5):807-11. PubMed ID: 22635030
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Vandenput I; Vergote I; Neven P; Amant F
Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
[TBL] [Abstract][Full Text] [Related]
8. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
9. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
10. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrence in a surveillance program for epithelial ovarian cancer.
Suprasert P; Chalapati W
Asian Pac J Cancer Prev; 2013; 14(12):7193-6. PubMed ID: 24460274
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract][Full Text] [Related]
17. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
19. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
20. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
